Leprosy and HIV, where are we at?
The impact of leprosy and HIV co-infection is an evolving picture. Surprisingly the outcomes that were feared, of more lepromatous disease has not materialised. But with the roll-out of antiretroviral therapy, the emergence of leprosy as Immune Reconstitution Inflammatory Syndrome is re-focusing attention on the characteristics of this important co-infection.
Diana N J
DN
Lockwood
Saba M
SM
Lambert
D017088:AIDS-Related Opportunistic Infections / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology; D000328:Adult; D044966:Anti-Retroviral Agents / Q000008:administration & dosage; D018791:CD4 Lymphocyte Count; D015897:Comorbidity; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology; D006801:Humans; D054019:Immune Reconstitution Inflammatory Syndrome / Q000139:chemically induced*; D007111:Immunity, Cellular; D007917:Leprostatic Agents / Q000008:administration & dosage; D007918:Leprosy / Q000150:complications* / Q000276:immunology / Q000503:physiopathology; D008297:Male; D009166:Mycobacterium leprae / Q000276:immunology / Q000302:isolation & purification
D044966:Anti-Retroviral Agents; D007917:Leprostatic Agents